Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
IPO Year:
Exchange: NYSE
Website: smith-nephew.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/4/2026 | Buy → Hold | Kepler | |
| 12/15/2025 | Outperform → Sector Perform | RBC Capital Mkts | |
| 10/14/2025 | $37.50 | Outperform → Mkt Perform | Bernstein |
| 4/25/2025 | Buy → Hold | HSBC Securities | |
| 3/12/2025 | Buy → Neutral | UBS | |
| 11/6/2024 | Buy → Hold | Berenberg | |
| 11/1/2024 | Buy → Hold | Deutsche Bank | |
| 7/24/2024 | Buy | Deutsche Bank | |
| 6/5/2024 | Neutral → Buy | UBS | |
| 11/28/2023 | Underweight → Equal Weight | Barclays |
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
Fastest customizable press release news feed in the world
Delivering versatility for airway procedures in a single, streamlined surgical solution Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces the commercial launch of its LYNX COBLATION Laryngeal Wand, a multi-purpose solution designed by laryngologists for laryngology. Backed by surgeon insights and the need for versatility, the LYNX Wand is designed with a long working length and also fine dissection and mass debulking capabilities to support procedures from supraglottis to trachea1,2 at low temperatures*3 with reduced risk of airway fire.†4-6 The LYNX COBLATION Laryngeal Wand advances airway procedural solutions thanks to several key differentiators,
Smith+Nephew ((LSE: SN, NYSE:SNN), the global medical technology company, today announces the publication of new consensus-based guidance - developed independently by expert clinicians for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany. Published in internationally recognised journal of surgery Die Chirurgie, the new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system. New consensus provides practical framework for post-surgical careThis new interdisciplinary consensus is the first in Germany to translate
Smith+Nephew ((LSE: SN, NYSE:SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany and has been published in the internationally recognised journal of surgery Die Chirurgie. The new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system. New guidelines link prevention strategies to improved health economics A recently published interdisciplinary expert consensus s
Issued on behalf of Conexeu Sciences Inc.A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization — in one of medicine's most consequential frontiers.RENO, Nev., June 16, 2026 /CNW/ -- American News Group News Commentary — There is a well-worn pattern in the life sciences: a company spends years on the science, goes public, and then — in the critical window right after listing — races to assemble the kind of leadership bench that can turn a promising platform into a real business. The names a young company recruits in that window say a great deal about its ambitions. On June 1
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (NASDAQ:CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further into manufacturing scale-up and regulatory preparation as it works toward a planned first-quarter 2027 510(k) submission. Companies mentioned: Conexeu Scien
Smith+Nephew ((LSE: SN, NYSE:SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, marking an important milestone in the clinical introduction of its latest handheld robotics technology. CORI XT Handheld Robotic Platform is designed to be the single handheld robotics platform for all orthopaedic needs - partial to revision knee, hip*, and anatomic and reverse shoulders - with a footprint tailored to the unique needs of hospitals and ambulatory surgical suites settings. These early cases represent the first use of CORI XT Platform across both knee and shoulder arthroplasty a
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF♢ Patient Monitoring System, a data-driven pressure injury prevention platform designed to help health care providers tackle the growing burden of hospital-acquired pressure injuries (HAPIs) by strengthening protocols and outcomes. The LEAF System uses a wearable sensor to monitor patient mobility and provide real-time turn status updates, helping to improve workflow efficiency, turn quality, and protocol adherence.1-3 Every year, approximately 60,000 annual deaths in the US are attributed to HAPIs,4 placing a $26.8B annual burden on the nationwide economy.5 For individu
Five companies. One overlapping story. The race to rebuild human tissue is moving from the lab into the public markets — fast. NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — There are weeks when the most interesting story on Wall Street isn't a single ticker. It's the through-line connecting several of them. The week of May 21, 2026 was one of those weeks. A brand-new Nasdaq listing in regenerative tissue arrived in the middle of a cluster of earnings beats, pipeline launches, and product approvals across a handful of related names — all of them, in one way or another, telling the same story: medicine is shifting from "replace" to "regenerate," and
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming European Wound Management Association (EWMA) Conference, Bremen between 6-8 May 2026. Demonstrating a long-term commitment to chronic wound management, Smith+Nephew is launching two new wound care innovations designed to support patient outcomes, simplify wound management and ease the clinical burden. This reflects the scale and urgency of a challenge that affects up to 14.9m people in Europe and consumes up to 4% of healthcare spend1. Fully supporting clinicians and patients across the continuum o
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces further compelling evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its CARTIHEAL AGILI-C Cartilage Repair Implant recently published in the American Journal of Sports Medicine (AJSM). The CARTIHEAL AGILI-C Cartilage Repair Implant resulted in higher overall Knee injury and Osteoarthritis Outcome Scores (KOOS) versus surgical standard of care* for all time points out to 60 months.1,2 Superior pain relief: Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 5-year perio
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - SMITH & NEPHEW PLC (0000845982) (Reporting)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Kepler downgraded Smith & Nephew from Buy to Hold
RBC Capital Mkts downgraded Smith & Nephew from Outperform to Sector Perform
Bernstein downgraded Smith & Nephew from Outperform to Mkt Perform and set a new price target of $37.50
HSBC Securities downgraded Smith & Nephew from Buy to Hold
UBS downgraded Smith & Nephew from Buy to Neutral
Berenberg downgraded Smith & Nephew from Buy to Hold
Deutsche Bank downgraded Smith & Nephew from Buy to Hold
Deutsche Bank initiated coverage of Smith & Nephew with a rating of Buy
UBS upgraded Smith & Nephew from Neutral to Buy
Barclays upgraded Smith & Nephew from Underweight to Equal Weight
Live finance-specific insights
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces it has completed the acquisition of Integrity Orthopaedics, further strengthening its sports medicine shoulder repair business with the most comprehensive suite of technologies available for rotator cuff repair (RCR). Integrity Orthopaedics is a US‑based, early‑stage commercial developer of Tendon Seam™, an innovative and disruptive biomechanical RCR system designed to significantly reduce re‑tear rates and improve patient outcomes versus the current standard of care. Tendon Seam™ allows for a novel repair stitch configuration with multiple points of fixation. Its patented microanchors, continuous sutu
New York, United States, March 03, 2025 (GLOBE NEWSWIRE) -- The global demand for wound care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Download Free Sample Report PDF @ https://straitsresearc
New York, United States, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The global demand for Wound Care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Get a Free Sample Copy of This Report https://stra
Adds two close-to-market innovative technologies to Healiva's® growing portfolio of end-to-end care for chronic wounds Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed. The first asset, EpiDex®, is an
LONDON, Jan. 19, 2022 /PRNewswire/ -- Smith+Nephew ((LSE: SN, NYSE:SNN), the global medical technology business, announces the acquisition of Engage Surgical, owner of the only cementless unicompartmental (partial) knee system commercially available in the US. This acquisition strongly supports Smith+Nephew's strategy for growth by transforming its business through innovation and acquisition, while also providing differentiation for its customers. The Engage Surgical Partial Knee System is a novel, modern cementless knee implant to serve a resurgent segment driven by the poten
Live Leadership Updates
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee. As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value. Ajay's experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy
STAUNTON, Va., Sept. 12, 2024 /PRNewswire/ -- Cadence, Inc., a leading provider of vertically integrated contract manufacturing solutions to the MedTech and Pharma markets, is pleased to announce the appointment of Bob White to its Board of Directors. Mr. White brings over 25 years of business leadership experience and a proven track record in operational excellence, technological innovation, and strategic growth to Cadence. Mr. White has demonstrated exceptional skills in managing global locations, having held senior positions at Medtronic, GE Healthcare, and IBM. He recent
This live feed shows all institutional transactions in real time.
SC 13D - SMITH & NEPHEW PLC (0000845982) (Subject)
SC 13G/A - SMITH & NEPHEW PLC (0000845982) (Subject)